DHA supports brain health and mood stability, addressing potential psychological adjustments during hormone optimization
Another observational trial published in September 2024 found that semaglutide was associated with reduced opioid overdose risk in patients with comorbid type 2 diabetes and opioid use disorder, and a study published in July last year also found that semaglutide was associated with a lower risk of regular tobacco use in patients with type 2 diabetes who were tobacco smokers, with semaglutide-treated patients seeking fewer healthcare resources to treat their tobacco addiction
10.1093/ajcn/nqaa177 Am J Clin Nutr
$50/month copay for eligible GLP-1s, including Wegovy, Zepbound (KwikPen), and the new oral pill Foundayo (orforglipron)*^ Available to Medicare Part D members who meet certain BMI and health criteria* Program runs July 1, 2026 December 31, 2027^ *For eligible Medicare Part D patients with qualifying GLP-1 medication prescription for weight management
This has led to increased interest in adjunctive weight loss interventions, including newer injectable medications specifically designed for weight management
There is no official clinical guidance, published interaction data, or regulatory framework governing the combined use of AOD 9604 and retatrutide
